Table 1.

Recent clinical trials of chimeric antigen receptor -T cells for breast cancer and other solid tumors.

Clinical trials government identifier	Target	Condition
NCT03696030	HER2	Malignant neoplasm metastatic, malignant neoplasm in the brain metastatic, malignant neoplasm in the leptomeninges, breast cancer, HER2-positive breast cancer
NCT04430595	HER2, GD2, and CD44v6	Breast cancer
NCT04107142	Natural killer G2D	Colorectal cancer, triple-negative breast cancer, sarcoma, nasopharyngeal carcinoma, prostate cancer, gastric cancer.
NCT04348643	Carcinoembryonic antigen	Solid-tumor lung cancer, colorectal cancer liver cancer, pancreatic cancer, gastric cancer, breast cancer
NCT02915445	EpCAM	Malignant neoplasm of nasopharyngeal tumor/node/metastasis staging distant metastasis, breast cancer recurrent
NCT02792114	Mesothelin	Breast cancer, metastatic HER2-negative breast cancer
NCT02706392	Receptor tyrosine kinase-like orphan receptor 1	Estrogen receptor-negative, HER2/Neu negative, progesterone receptor-negative, recurrent adult acute lymphoblastic leukemia, recurrent mantle cell lymphoma, refractory chronic lymphocytic leukemia, stage IV breast cancer AJCC v6 and v7Stage IV, non-small cell lung cancer AJCC v7, triple-negative breast carcinoma
NCT01837602	cMet RNA	Metastatic breast cancer, triple-negative breast cancer
NCT03635632	GD2	Relapsed neuroblastoma, refractory neuroblastoma, relapsed osteosarcoma relapsed Ewing sarcoma, relapsed rhabdomyosarcoma, uveal melanoma, phyllodes breast tumor
NCT02541370	CD133	Liver cancer, pancreatic cancer, brain tumor, breast cancer, ovarian tumor, colorectal cancer, acute myeloid and lymphoid leukemia
NCT04025216	TnMucin 1	Non-small cell lung cancer, ovarian cancer, fallopian tube cancer, triple-negative breast cancer, multiple myeloma, pancreatic ductal adenocarcinoma

HER2; Human epidermal growth factor receptor 2.